Welcome to our dedicated page for Vivopower International Plc news (Ticker: VIVO), a resource for investors and traders seeking the latest updates and insights on Vivopower International Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vivopower International Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vivopower International Plc's position in the market.
Meridian Bioscience has launched the Air-Dryable™ Direct DNA qPCR Plant Mix, a groundbreaking solution for agricultural biotechnology. This product allows multiplexed molecular field-tests without the need for DNA purification, significantly enhancing efficiency. With its unique polymerase and high 4x concentration, the Mix enables the development of stable assays at room temperature, reducing costs and manufacturing time. Dr. Lourdes Weltzien emphasized its potential to transform testing processes, allowing manufacturers to save time and improve performance in crop disease management.
Meridian Bioscience reported strong financial results for Q2 2021, with consolidated net revenues of $85.3 million, a notable increase of 49% year-over-year. The Life Science segment surged 139% year-over-year to $53.3 million, largely driven by COVID-19 products. However, Diagnostics segment revenues fell 9% year-over-year, despite a 5% increase from Q1 2021. Operating income rose significantly to $34.2 million with an adjusted operating margin of 38%. Guidance for FY2021 was adjusted, forecasting consolidated revenues between $305 million and $335 million.
Meridian Bioscience has launched the Lyo-Ready™ DNA LAMP Mix, aimed at enhancing the development of ambient temperature-stable LAMP assays. This product supports point-of-care molecular diagnostics and eliminates the need for thermocyclers, thereby reducing costs. Designed as a glycerol-free, 4x concentrated mix, it allows for faster development of room temperature stable assays with high sensitivity and specificity. The company continues to innovate in diagnostic testing solutions, responding to growing demands in the healthcare sector.
Meridian Bioscience (NASDAQ: VIVO) will release its second quarter fiscal 2021 financial results on May 7, 2021. CEO Jack Kenny and CFO Bryan Baldasare will conduct a conference call at 10:00 a.m. ET to discuss the results. Investors can dial in using the numbers provided for participation, with a replay available for 14 days post-call. Meridian Bioscience focuses on innovative diagnostic products and life science raw materials for various applications, serving over 70 countries globally.
On April 1, 2021, Meridian Bioscience announced a 510(k) submission to the FDA for its new Curian® Campy assay, enhancing its gastrointestinal testing offerings. The assay detects Campylobacter spp. in human stool and aims to streamline testing processes with rapid, objective results. Meridian positions the Curian® platform as a leading solution, reducing user variability in test interpretation. This move strengthens Meridian's role in the diagnostic testing market, essential for healthcare systems focusing on gastrointestinal diseases.
Meridian Bioscience, Inc. (NASDAQ: VIVO) has launched its new Air-Dryable Direct DNA qPCR Blood Mix, aimed at enhancing molecular diagnostic assays directly from whole blood, serum, or plasma. This innovative product allows for room-temperature stable diagnostics without the need for DNA purification, addressing challenges posed by PCR inhibitors and mitigating the costs and complexities associated with traditional methods. The technology facilitates faster, simpler assays, enabling manufacturers to enhance their workflow and efficiency in cancer detection.
Meridian Bioscience, a leading provider of diagnostic testing solutions, announced its participation in the H.C. Wainwright Global Life Sciences 2021 Virtual Conference. The CEO, Jack Kenny, will present a pre-recorded session accessible from March 9, 2021. The presentation link will be available on the company's Investor Relations website for 90 days. Meridian is dedicated to delivering innovative diagnostic products and raw materials for various applications, including human and environmental testing. The company's stock is traded on NASDAQ under the symbol VIVO.
Meridian Bioscience (NASDAQ: VIVO) has announced the withdrawal of its Emergency Use Authorization (EUA) application for its SARS-CoV-2 molecular diagnostic test on the Revogene® platform. Following communication with the FDA, the company clarified that it cannot distribute the test until EUA approval is granted. This is a reversal from their earlier statement regarding resuming shipments upon re-submission of the EUA application. The company emphasizes that all forward-looking statements are subject to various risks and uncertainties that could impact future performance.
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced the withdrawal of its Emergency Use Authorization (EUA) application for the SARS-CoV-2 molecular diagnostic test on the Revogene platform. This decision follows a request for additional information from the FDA. Meridian plans to conduct a new clinical validation and Limit-of-Detection study by the end of March 2021, with the intention to re-submit the EUA application afterward. The company anticipates resuming shipments of the test during the third fiscal quarter, with financial guidance updates to be discussed on May 7, 2021.
On February 16, 2021, Meridian Bioscience (NASDAQ: VIVO) announced updates regarding its application for Emergency Use Authorization (EUA) of its SARS-CoV-2 molecular diagnostic test on the Revogene® platform. Following a communication from the FDA requesting more information, the company has opted to pause shipments of the test kits while it prepares a detailed response. Meridian is dedicated to improving diagnostic solutions and provides essential life science raw materials globally.